Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 2:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ewing's Osteosarcoma Clear all
Completed Phase 2 Interventional Results available

Stem Cell Transplantation in Patients With High-Risk and Recurrent Pediatric Sarcomas

NCT00043979
View directory record Official record
Conditions
Sarcoma
Interventions
F-18 Fluorodeoxyglucose, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, doxorubicin hydrochloride, etoposide, fludarabine phosphate, melphalan, prednisone, sirolimus, tacrolimus, vincristine sulfate, peripheral blood stem cell transplantation, Filgrastim, Peripheral Blood Stem Cell donation
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
5 Years to 35 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

NCT03449901
View directory record Official record
Conditions
Soft Tissue Sarcoma
Interventions
pegylated arginine deiminase, Gemcitabine, Docetaxel, Tumor biopsy, Research blood draw
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
10 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
4
States / cities
Palo Alto, California • Santa Monica, California • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 13, 2026, 2:41 PM EDT
Not listed Phase 1Phase 2 Interventional

Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors

NCT00179816
View directory record Official record
Conditions
Ewing's Sarcoma, Soft Tissue Sarcoma, Hepatoblastoma, Hodgkin's Disease, Germ Cell Tumor
Interventions
High-Dose Chemotherapy with Tandem PBSC Rescue.
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 10, 2010 · Synced Sep 13, 2026, 2:41 PM EDT
Recruiting Phase 1Phase 2 Interventional

DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma

NCT06892678
View directory record Official record
Conditions
Osteosarcoma Recurrent, Ewing's Tumor Recurrent
Interventions
DFMO
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
Up to 39 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer

NCT00002466
View directory record Official record
Conditions
Kidney Cancer, Sarcoma
Interventions
cyclophosphamide, doxorubicin hydrochloride, etoposide, ifosfamide, vincristine sulfate, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1990 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Sep 13, 2026, 2:41 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Stereotactic Body Radiotherapy (SBRT) for Pulmonary Metastases in Ewing Sarcoma, Rhabdomyosarcoma, and Wilms Tumors

NCT02581384
View directory record Official record
Conditions
Ewing Sarcoma, Rhabdomyosarcoma, Wilms Tumor, Osteosarcoma, Non-Rhabdomyosarcoma Soft Tissue Sarcoma, Nos, Renal Tumor, Rhabdoid Tumor, Clear Cell Renal Cell Carcinoma, Sarcoma, Sarcoma, Ewing, Soft Tissue Sarcoma
Interventions
Stereotactic Body Radiotherapy (SBRT)
Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Sep 13, 2026, 2:41 PM EDT
Temporarily Not Available No phase listed Expanded access

Expanded Access of Vigil in Solid Tumors

NCT03842865
View directory record Official record
Conditions
Solid Tumor, Ewing Sarcoma, Ewing's Tumor Metastatic, Ewing's Sarcoma Metastatic, Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
Interventions
Vigil
Biological
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy

NCT01222767
View directory record Official record
Conditions
Ewing's Sarcoma, Primitive Neuroectodermal Tumor (PNET), Askin's Tumor of the Chest Wall, Extraosseous Ewing's Sarcoma (EOE)
Interventions
Zalypsis
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
16 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Santa Monica, California • Memphis, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

NCT00001564
View directory record Official record
Conditions
Ewing's Sarcoma, Rhabdomyosarcoma
Interventions
EF-1 Peptide, EF-2 Peptide, PXFK Peptide, E7 Peptide, IL-2, IL-4, GM-CSF, CD40 Ligand
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma

NCT00743509
View directory record Official record
Conditions
Osteosarcoma
Interventions
Cyclophosphamide and Sirolimus
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
16 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 27, 2015 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors

NCT00070109
View directory record Official record
Conditions
Previously Treated Childhood Rhabdomyosarcoma, Recurrent Childhood Rhabdomyosarcoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor
Interventions
trabectedin, pharmacological study
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
11
States / cities
Little Rock, Arkansas • Madera, California • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Not applicable Interventional

Effects of Preoperative Physical Therapy in Patients With Lower Extremity Malignancy

NCT01674101
View directory record Official record
Conditions
Osteosarcoma, Ewing's Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Malignant Peripheral Nerve Sheath Sarcoma, Malignant Fibrous Histiocytoma of the Bone, Chondrosarcoma of the Bone
Interventions
Endurance, Strengthening, Stretching, Home exercise program
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
6 Years to 30 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

NCT01518413
View directory record Official record
Conditions
Rhabdomyosarcoma and Other Soft Tissue Sarcomas, Ewing's Sarcoma Family of Tumors, Osteosarcoma, Neuroblastoma, Brain Tumors
Interventions
sorafenib, irinotecan
Drug
Lead sponsor
HMeany
Other
Eligibility
2 Years to 22 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2015 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 2 Interventional

New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma

NCT00001335
View directory record Official record
Conditions
Ewing's Sarcoma, Neuroblastoma, Rhabdomyosarcoma
Interventions
ADR-529, Topotecan, G-CSF
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 13, 2026, 2:41 PM EDT
Terminated Phase 2 Interventional Results available

A Study of R1507 in Participants With Recurrent or Refractory Sarcoma

NCT00642941
View directory record Official record
Conditions
Sarcoma
Interventions
RG1507
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
2 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
22
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 1 Interventional Results available

Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

NCT00474760
View directory record Official record
Conditions
Sarcoma, Ewing's
Interventions
CP-751,871
Drug
Lead sponsor
Pfizer
Industry
Eligibility
9 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
2
States / cities
Ann Arbor, Michigan • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2013 · Synced Sep 13, 2026, 2:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

NCT05440786
View directory record Official record
Conditions
Sarcoma, Ewing, Neoplasm Metastasis
Interventions
Abemaciclib, Irinotecan, Temozolomide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 39 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Phoenix, Arizona • Los Angeles, California • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors

NCT00001209
View directory record Official record
Conditions
Neuroectodermal Tumor, Primitive, Neuroepithelioma, Osteosarcoma, Sarcoma, Sarcoma, Ewing's
Interventions
vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1986 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.

NCT01353625
View directory record Official record
Conditions
Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma, Chronic Lymphocytic Leukemia, Neoplasm Metastasis
Interventions
CC-115
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 1Phase 2 Interventional

Aerosol L9-NC and Temozolomide in Ewing's Sarcoma

NCT00492141
View directory record Official record
Conditions
Ewing's Sarcoma
Interventions
Temozolomide, L9-NC
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2012 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Phase I Study of Olaparib and Temozolomide for Ewings Sarcoma or Rhabdoomyosarcoma

NCT01858168
View directory record Official record
Conditions
Ewing Sarcoma, Rhabdomyosarcoma
Interventions
Olaparib, Temozolomide, Irinotecan
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
16 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
5
States / cities
Boston, Massachusetts • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

NCT02890758
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Myeloproliferative Syndromes, Plasma Cell Myeloma, Colon Carcinoma, Adenocarcinoma of Rectum, Soft Tissue Sarcoma, Ewing's Sarcoma, Rhabdomyosarcoma
Interventions
Natural Killer (NK) Cells, ALT803
Biological
Lead sponsor
Brenda Cooper, MD
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2023 · Synced Sep 13, 2026, 2:41 PM EDT
Completed Phase 2 Interventional Results available

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

NCT02511132
View directory record Official record
Conditions
Ewing's Sarcoma
Interventions
Vigil, Temozolomide, Irinotecan, Gemcitabine, Docetaxel
Biological · Drug
Lead sponsor
Gradalis, Inc.
Industry
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
6
States / cities
Little Rock, Arkansas • Miami, Florida • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Sep 13, 2026, 2:41 PM EDT
Recruiting No phase listed Observational

Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas

NCT03442465
View directory record Official record
Conditions
Bone Sarcoma, Osteosarcoma, Chondrosarcoma, Ewing's Sarcoma, Osseous Sarcoma, Bone Neoplasm
Interventions
Toronto Extremity Salvage Score, Musculoskeletal Tumor Society Score, Timed Get Up and Go Test, Orthogonal Radiographs, Weight Bearing for lower extremities only, Range of Motion
Behavioral · Diagnostic Test
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
4 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Harrison, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 13, 2026, 2:41 PM EDT